جست‌وجوی استاد و پژوهشگر

استاد راهنما، استاد دانشگاه یا پژوهشگر مناسب برای مسیر پژوهشی‌تان را پیدا کنید و با او ارتباط بگیرید.

نمایش ۶۱-۷۵ از ۳۰۸ استاد راهنما

اطلاعات این پروفایل‌ها از صفحات عمومی دانشگاه‌ها جمع‌آوری شده و ممکن است به‌روز نباشد.

Hilary Davies-Kershawمشاهده پروفایل

استادیار

Institute of Hygiene and Tropical MedicinePortugal

Dr. Hilary Davies-Kershaw is an Assistant Professor in the Department of Population Health within the Faculty of Epidemiology and Population Health at the London School of Hygiene & Tropical Medicine (LSHTM). She serves as Programme Director for the MSc Nutrition for Global Public Health and has been at LSHTM since 2019, initially as a Research Fellow before her promotion to Assistant Professor in 2022. Her educational background includes a PhD in Epidemiology and Health from University College London, a Masters in Nutrition from Stellenbosch University, a PG Medical Honours in Nutrition and Dietetics from the University of Cape Town, and a BSc in Biochemistry and Psychology from the same institution. She also holds a PG Certificate in Higher Education from St Mary's University. Davies-Kershaw is an established nutrition epidemiologist and registered dietitian with expertise spanning maternal and child health, older adult nutrition, and malnutrition prevention. Her research employs mixed methods approaches, mother-child cohort studies, and analysis of longitudinal datasets including the English Longitudinal Study of Ageing, Hospital Episode Statistics, The Health Improvement Network and SUAAHARA. She has extensive international experience through the UKRI GCRF funded Action Against Stunting Hub across India, Indonesia and Senegal. Her recent publications demonstrate strong trends in global nutrition interventions, particularly focusing on stunting prevention, complementary feeding practices, and the intersection of mental health and nutrition across the life course. She frequently collaborates with international researchers on multi-country studies addressing nutrition challenges in low-resource settings. Davies-Kershaw actively supervises PhD students including Lyndsay Spencer (University of Surrey), Audrey Mwendapole and Diane Baik (LSHTM), with research focusing on military spouse maternal experiences, complementary feeding practices in Zambia, and treatment of malnutrition in Vietnam. She has secured significant grant funding through UKRI GCRF and ELRHA for her work on undernutrition prevention interventions. Her work integrates clinical dietetics expertise with population-level epidemiological approaches, conducting field research across multiple continents while maintaining strong NHS connections through her prior clinical experience as a Community Senior Dietitian with NHS Wandsworth.

پروفایل رسمی دانشگاه

Olga Goloubevaمشاهده پروفایل

استاد

University of Maryland, BaltimoreUnited States

Dr. Olga Goloubeva serves as a Professor in the School of Epidemiology & Public Health at the University of Maryland School of Medicine. Her primary appointment focuses on biostatistical applications in cancer research with extensive collaboration across oncology departments. Her research concentrates on design and statistical analysis of clinical trials (Phases I-III), biomarker evaluation for cancer diagnostics, and prognostic modeling using longitudinal and hierarchical data structures. She specializes in integrating proteomics and genomics data into cancer survival models, with particular expertise in analyzing high-dimensionality datasets from SEER-Medicare and NCDB population-based cancer registries. Her work addresses critical gaps in understanding treatment disparities across racial and socioeconomic groups. Analysis of her 15 most recent publications reveals consistent focus on hematologic malignancy outcomes (AML, lymphoma, myeloma), CAR-T therapy response prediction , and cardio-oncology interactions . Methodologically, she employs advanced biostatistical techniques including real-world evidence analysis, comparative effectiveness research, and complex survival modeling. International Topical Expert for Cancer Centre Site Visits (Innsbruck, 2011) Voting Member for International Cancer Research Evaluations (2011) Biostatistics Expert for Swiss National Science Foundation (2015) Statistical Consultant for NIH/NIA Alzheimer's Disease Trials (2008-2012) Member of DSM Boards for NIH Clinical Trials Dr. Goloubeva actively serves as PI or Co-PI on multiple federally funded projects including NCI Cancer Center Support Grants and VA Merit Awards. Her statistical consultancy spans industry collaborations with biotech firms and international trials through the International Atomic Energy Agency. Current research examines ethnic disparities in multiple myeloma outcomes and behavioral interventions for low-income patient populations.

پروفایل رسمی دانشگاه

Tobias Damمشاهده پروفایل

پژوهشگر

St. Pölten University of Applied SciencesAustria

Tobias Dam serves as an Academic Professional at the Institute of IT Security Research within the Department of Computer Science and Security at St. Pölten University of Applied Sciences. His work focuses on practical cybersecurity challenges with emphasis on open-source software ecosystems, data space security, and web-based threats. Based in the B-Campus-Platz 1 location, he actively contributes to both research and educational initiatives in IT Security. His educational background includes completing HTL St. Pölten's Department of IT/Computer Science program from 2008-2013, followed by a Bachelor's degree in IT Security at St. Pölten University of Applied Sciences from 2013-2016. He gained practical experience in 2015 working on software development, security, and configuration management in the "upribox" project. Since 2016, he has been pursuing a Master's degree in Information Security at the same institution. Dr. Dam's research spans multiple critical areas in modern cybersecurity, with particular expertise in analyzing vulnerabilities in open-source software ecosystems. His work on critical open-source software databases represents significant contributions to understanding the "health status" of important open-source projects. He has also made notable advances in data space security, developing policy patterns for usage control, and conducting extensive analyses of web-based threats including typosquatting, pop-up scams, and cryptojacking. His research uniquely bridges theoretical frameworks with empirical analysis of real-world security issues, often examining how privacy techniques like k-anonymity impact machine learning classifiers and how data deletion affects model integrity. His publication record demonstrates consistent contributions to major cybersecurity conferences and journals, with recent work focusing on dataspace connector implementations, critical open-source software metrics, and vulnerability assessment in open-source packages. His research trajectory shows increasing specialization in the security challenges of modern data ecosystems while maintaining strong connections to practical implementation concerns. Through his video presentations on cloud services versus self-operated programs and secure remote corporate IT access, Dr. Dam actively engages in knowledge transfer to broader technical audiences beyond traditional academic publication channels.

پروفایل رسمی دانشگاه

Yuliya Vladimirovna Lokhnyginaمشاهده پروفایل

دانشیار

Duke UniversityUnited States

Yuliya Vladimirovna Lokhnygina serves as Associate Professor of Biostatistics & Bioinformatics at Duke University, where she is a key member of the Duke Clinical Research Institute (DCRI) and Biostatistics, Epidemiology, and Research Design (BERD) Methods Core. Her office is located at 200 Morris Street, Durham, NC, and she contributes statistical expertise to clinical research across multiple medical disciplines. Her academic foundation includes: Ph.D. in Statistics from North Carolina State University (2004) M.S. in Statistics from Cornell University (2001) M.S. in Applied Mathematics from Moscow Institute of Physics and Technology, Russia (1999) Dr. Lokhnygina's research centers on advanced statistical methodologies for clinical investigations, with core expertise in survival analysis, adaptive clinical trial designs, causal inference in observational studies, and semiparametric inference. Her methodological innovations directly address challenges in complex clinical settings, particularly in infectious disease management and transplantation medicine. Analysis of her 2024-2025 publications reveals a strong focus on clinical trial methodology (win statistics for hierarchical endpoints), nephrology (kidney transplantation disparities), infectious diseases (antifungal strategies, HIV care during pandemics), and surgical outcomes. Her work consistently bridges theoretical biostatistics with practical clinical applications through high-impact collaborations. She currently leads 27 major research grants including NIH R01 awards for antifungal strategies (LAmB-FAST), neonatal malaria testing (INTREPiD), and kidney transplant equity (STEPS), alongside AHRQ-funded studies on C. difficile prevention and PCORI-supported interventions for living kidney transplants. These projects demonstrate substantial funding support and interdisciplinary collaboration across Duke and national institutions. Within the BERD Methods Core and DCRI, Dr. Lokhnygina operates in a premier clinical research ecosystem that supports over 500 active studies. Her role involves statistical leadership for large-scale trials including TACT2 (chelation therapy) and Limbix Spark (digital mental health interventions), contributing to Duke's reputation in translational research.

پروفایل رسمی دانشگاه

Jesper Kroghمشاهده پروفایل

استاد بالینی

University of CopenhagenDenmark

Jesper Krogh serves as a Clinical Professor within the Department of Clinical Medicine at the University of Copenhagen, specializing in Internal Medicine: Endocrinology. His clinical and research activities are centered at Copenhagen University Hospital, with direct contact via phone (+4525535485) and email (jekrog@regionsjaelland.dk) at Blegdamsvej 3, 2200 Copenhagen N. His primary research domains include: Endocrinology (focusing on diabetes subtypes and hormonal disorders) Diabetes pathophysiology and treatment (particularly MODY3 and SGLT2 inhibitors) Neuroendocrinology and brain metabolism interactions Metabolic disorders in cardiovascular contexts Neuroendocrine tumor management Analysis of his 43 research outputs reveals a pronounced emphasis on translational endocrinology, with 2024-2025 publications predominantly investigating SGLT2 inhibitor efficacy in genetic diabetes forms, primary aldosteronism diagnostics, insulin resistance mechanisms, and neuroendocrine tumor outcomes. His work frequently employs clinical trial designs and systematic reviews, often in collaboration with the Copenhagen Neuroendocrine Tumour Centre, targeting therapeutic advancements for complex endocrine conditions. No scientific awards are documented in the provided materials. While student mentorship details are absent from the text, his collaborative publications with institutions like Region Zealand indicate active clinical supervision. Grant funding specifics remain undisclosed, though his research scope suggests involvement in diabetes and oncology-focused funding initiatives. Dr. Krogh maintains strong institutional ties to the Copenhagen Neuroendocrine Tumour Centre, evidenced by co-authorship on multiple tumor studies, and participates in multidisciplinary teams addressing endocrine malignancies and metabolic disorders.

پروفایل رسمی دانشگاه

Eric Smallمشاهده پروفایل

استاد

University of California, San FranciscoUnited States

Dr. Eric Small is a Professor in the Department of Medicine at the University of California, San Francisco (UCSF), School of Medicine. He is a leading clinical and translational researcher in advanced prostate cancer. B.S. in Biology, Stanford University (1980) M.D., Case Western Reserve University (1985) Residency and Fellowship in Internal Medicine and Cancer Research at Beth Israel Hospital and UCSF Dr. Small's research focuses on clinical and translational aspects of advanced prostate cancer, including the development of novel agents targeting the androgen receptor (e.g., abiraterone, apalutamide) and immunotherapies (e.g., sipuleucel-T, ipilimumab). His work emphasizes understanding resistance mechanisms, particularly through genomic and epigenomic studies of metastatic disease. He has led major initiatives such as the Stand Up to Cancer/Prostate Cancer Foundation Dream Team. His extensive publication record, particularly in high-impact journals from 2023–2025, reflects a strong focus on resistance mechanisms, lineage plasticity, genomic characterization, and clinical trial outcomes in metastatic and castration-resistant prostate cancer. His work integrates genomics, transcriptomics, and clinical data to advance precision oncology. Scientific Awards: Alpha Omega Alpha Honor Medical Society (1984) UCSF Division of Hematology-Oncology Faculty Research Award (2001) Richard L. Schilsky CALGB Award for Clinical Research (2011) UCSF Academic Senate Faculty Research Lecture in Clinical Science (2011) Fellow of the American Society of Clinical Oncology (FASCO) (2015) Dr. Small holds significant leadership roles, including Co-Leader of the UCSF Prostate Cancer Program and Chief Scientific Officer of the UCSF Helen Diller Family Comprehensive Cancer Center. He serves on the ASCO Board of Directors and chairs multiple external advisory boards. He has been Principal Investigator on major grants, including a $10 million SU2C/PCF award, and has mentored numerous collaborators and trainees through large multi-institutional research teams. He is actively involved in national and international consensus efforts, such as the Advanced Prostate Cancer Consensus Conference (APCCC), shaping clinical guidelines and identifying future research directions.

پروفایل رسمی دانشگاه

Jan Oldenburgمشاهده پروفایل

استاد

University of OsloNorway

Jan Oldenburg serves as Professor II in the Division of Medicine and Laboratory Sciences at the University of Oslo's Faculty of Medicine, based at Akershus University Hospital. His clinical and research activities focus on urologic malignancies with particular emphasis on testicular, prostate, and renal cancers. His research interests center on urologic oncology , specifically the management of testicular germ cell tumors, prostate cancer therapeutics, and renal cell carcinoma. Key areas include platinum-based chemotherapy toxicity, cancer survivorship issues, and the development of evidence-based clinical guidelines. His work frequently addresses long-term complications in cancer survivors such as neurotoxicity, ototoxicity, and endocrine dysfunction. His publication portfolio demonstrates consistent leadership in major international guideline initiatives, including the EAU-EANM-ESTRO-ESUR-ISUP-SIOG prostate cancer guidelines and ESMO-EURACAN testicular cancer guidelines. Recent work shows increasing focus on targeted therapies (PARP inhibitors), immunotherapy combinations, and real-world evidence in metastatic disease settings. As an active contributor to clinical guideline development, he participates in multiple European Association of Urology and ESMO consensus panels. His research utilizes Norwegian cancer registries and population-based cohorts to investigate survivorship issues and treatment outcomes. He maintains active clinical trial involvement, particularly in phase III studies evaluating novel combinations for metastatic prostate cancer (TALAPRO-2) and advanced urothelial carcinoma (CheckMate 901). His work bridges clinical practice with translational research through the Translational Cancer Research group at Akershus University Hospital.

پروفایل رسمی دانشگاه

Luke Healesمشاهده پروفایل

مدرس ارشد

Central Queensland University (CQUniversity Australia)Australia

Dr. Luke Heales is a Senior Lecturer in Musculoskeletal Physiotherapy and Postgraduate Research Coordinator at Central Queensland University’s School of Health, Medical and Applied Sciences. He holds a PhD from The University of Queensland (Dean’s Award), a Bachelor of Health Science (Valedictorian) from Auckland University of Technology, and a Postgraduate Certificate in Tertiary Education from CQUniversity. Specialises in upper limb injury rehabilitation and persistent tendon pain Active researcher in occupational rehabilitation and beach accessibility for people with disability Recipient of multiple teaching awards including the Australian Awards for University Teaching (2021) Secured over $500,000 in competitive research and teaching grants His recent publications focus on tendinopathy management, biomechanical responses to taping/orthoses, and accessibility studies for inclusive beach environments. He supervises 4 research higher degree students and teaches musculoskeletal physiotherapy at undergraduate and postgraduate levels. Scientific awards and grants include: Deans Award for Outstanding Research Higher Degree (2015) 3 Minute Thesis Competition awards (2015) Summer Research Scholarships (2010-2011) Best Research Project award (2011)

پروفایل رسمی دانشگاه

James Davisمشاهده پروفایل

استاد

University of California, San FranciscoUnited States

James Davis, MD, FACS is a Professor of Clinical Surgery at the University of California, San Francisco (UCSF) School of Medicine and serves as the Chief of Trauma at Community Regional Medical Center. He holds the Steven N. Parks Endowed Chair of Surgery at UCSF Fresno and directs the Acute Care Surgery Fellowship Program , which was the first of its kind in California. His career spans multiple leadership roles in trauma systems development, including chairing the Central California Regional Trauma Coordinating Committee and national initiatives through the American College of Surgeons . University of California San Diego, BA Biology (1977) University of Iowa School of Medicine, MD (1981) Residency: Maricopa Medical Center (1986) Fellowship: UC San Diego Trauma (1987) Dr. Davis's research focuses on trauma surgery , acute care surgery , and domestic violence prevention , with over 150 PubMed publications. His work examines injury patterns, resuscitation metrics, and surgical outcomes while challenging conventional trauma paradigms like splenic preservation and vascular injury management. Recent studies analyze endovascular approaches, metabolic markers of shock, and firearm injury prevention strategies. His 2015-2022 publications highlight advancements in trauma laparotomy , critical care analgesia , and trauma systems optimization . Key collaborations include co-investigators Krista Kaups, John Bilello, and Amy Kwok across institutions like UCSD and Landstuhl Regional Medical Center. UCSF Fresno Faculty Research Award (1996) Henry J. Kaiser Teaching Award – Honorable Mention (1994) Senior Visiting Surgeon, American Association for the Surgery of Trauma (2011) As Region 9 Chief for the American College of Surgeons Committee on Trauma, Dr. Davis has standardized trauma care across five counties. He serves on the Journal of Trauma and Acute Care Surgery Editorial Board and the Western Trauma Association , shaping national guidelines for peripheral vascular injuries and penetrating neck trauma.

پروفایل رسمی دانشگاه

Ana Violeta Girãoمشاهده پروفایل

پژوهشگر

University of AveiroPortugal

Ana Violeta Girão is a Researcher at the University of Aveiro's Department of Materials and Ceramic Engineering, affiliated with CICECO - Centre for Research in Ceramics and Composite Materials. She holds a PhD in Civil Engineering from the University of Leeds (2007) and has extensive experience in nanostructured materials research, carbon-based materials for environmental applications, and advanced microscopy techniques. Education: BSc Chemistry (2001, University of Lisbon), MSc Applied Analytical Chemistry (2003, University of Lisbon), PhD Civil Engineering (2007, University of Leeds). Professional roles include R&D Head at SRE (fuel cells) and Post-Doc researcher at UA-CICECO (2010-2016). Current research focuses on nanomaterials for pollution sensing, electrochemical applications, and sustainable materials development. Her work integrates transmission/scanning electron microscopy (TEM/SEM), atomic force microscopy (AFM), and real-time structural dynamics analysis. Research emphasizes practical applications in environmental remediation, biomedical sensors, and eco-friendly materials. Publications (49 journal articles, 4 book chapters) highlight advancements in electrochemical coatings, microplastic toxicity, and biobased nanocomposites. Awards include EPSRC and FCT funding scholarships. Teaching experience includes labs on electron microscopy and materials characterization at University of Aveiro and Leeds. Supervised multiple MSc and industrial project students. Active in cross-sector collaborations, including projects with Bosch Thermal Technology. Scientific contributions span 30+ SCI papers and ongoing expansion of research methods in nanomaterials characterization.

پروفایل رسمی دانشگاه

Peter Ghijbenمشاهده پروفایل

پژوهشگر ارشد

Monash UniversityAustralia

Peter Ghijben is a Senior Research Fellow at the Centre for Health Economics (CHE), part of the Faculty of Business and Economics at Monash University. He is actively engaged in research that directly informs healthcare funding decisions in Australia and internationally, particularly through health technology assessment and economic evaluation. He is the deputy-head of the Health Technology Assessment programme at CHE and is accepting PhD students. Dr Ghijben holds academic qualifications in pharmacy, economics, and health economics, which underpin his interdisciplinary research approach. His work contributes to several United Nations Sustainable Development Goals, particularly those related to good health and well-being. His primary research interests lie in healthcare decision-making, cost-effectiveness analysis alongside clinical trials, decision analytic modelling, healthcare utilisation research, causal inference using real-world data, preferences in health, and price negotiations in health markets. His expertise bridges clinical, economic, and policy domains, focusing on improving healthcare efficiency and equity. The recent publications highlight a strong focus on health policy evaluation, particularly in smoking cessation, cancer treatment assessment, and mental health interventions. His work frequently involves collaboration with government agencies such as the Pharmaceutical Benefits Advisory Committee (PBAC) and the National Disability Insurance Scheme (NDIS), producing commissioned reports that directly influence public health decisions. There is a consistent emphasis on real-world data, behavioural responses, and the economic implications of health interventions. Dr Ghijben has been involved in multiple research projects as a Chief or Associate Investigator, covering areas such as rare genetic disorders, cancer survival monitoring, and tobacco control. These projects reflect an applied, policy-relevant research agenda aimed at improving health system outcomes. He has authored or co-authored several peer-reviewed articles in journals like Health Economics , Australian and New Zealand Journal of Psychiatry , and Nicotine and Tobacco Research , as well as commissioned reports for the Australian Department of Health and Aged Care. His research has been widely disseminated, with coverage in news outlets and engagement on social media platforms. Dr Ghijben collaborates extensively with researchers across Monash University and external institutions, working on interdisciplinary teams to address complex health system challenges. His leadership in the HTA programme and involvement in national advisory frameworks underscore his role as a key contributor to evidence-based health policy in Australia.

پروفایل رسمی دانشگاه

Marte Lie Høivikمشاهده پروفایل

استاد

University of OsloNorway

Marte Lie Høivik is a Professor at the University of Oslo's Institute of Clinical Medicine, Department of Gastroenterology and Hepatology. She serves as Senior Consultant and Head of the IBD Unit at Oslo University Hospital, leading the IBD research group and directing the IBSEN III study. Her research focuses on clinical and registry-based epidemiology in inflammatory bowel disease (IBD), with emphasis on clinical effectiveness, quality studies, prognostic research, and biomarker identification. Her work leverages large population-based cohorts like IBSEN to investigate disease course, treatment outcomes, and quality-of-life impacts. Recent publications reveal strong trends in risk prediction modeling, microbiome analysis, therapeutic drug monitoring, and real-world treatment effectiveness. Her team frequently examines understudied aspects like fatigue in remission, dietary impacts, and sex/gender differences in IBD outcomes using longitudinal cohort designs. Høivik actively supervises research within the IBSEN III cohort and collaborates extensively across Nordic countries on IBD epidemiology. Her team has published over 30 papers since 2021 in high-impact journals including Nature , Gastroenterology , and The Lancet Gastroenterology & Hepatology . She leads multiple research projects including the IBSEN III cohort study and NORDTREAT, with current funding supporting investigations into biomarkers, treatment strategies, and long-term disease outcomes in inflammatory bowel disease.

پروفایل رسمی دانشگاه

Imran Arifمشاهده پروفایل

دانشیار بالینی

University of CincinnatiUnited States

Dr. Imran Arif serves as Associate Professor of Clinical Medicine at the University of Cincinnati College of Medicine, where he directs the Cardiac Catheterization Laboratory at the Cincinnati VA Medical Center and co-leads the Interventional Cardiology Fellowship Program. His dual academic-clinical role bridges the Department of Medicine's Section of Interventional Cardiology with Veterans Affairs cardiovascular services since 2008. Education highlights: MBBS (Medicine/Bachelor of Surgery) from King Edward Medical College Lahore (1994) Internal Medicine Residency at Marshall University School of Medicine (2000) Cardiovascular Disease Fellowship at Marshall University (2003) Interventional Cardiology Fellowship at University of Cincinnati (2008) His research centers on structural and coronary interventions , with expertise in atherosclerotic disease, peripheral vascular procedures, and hemodynamic diagnostics. Pioneering work on lesion flow coefficient and pressure drop metrics provides hyperemia-free alternatives to traditional coronary physiology assessments. Current studies focus on transcatheter valve therapies and vascular interventions for complex arterial disease. Recent publications (2012-2023) reveal three dominant research trajectories : 1) Hemodynamic innovation (60% of recent work) developing pressure-based stenosis diagnostics, 2) Structural heart interventions (25%) including valve-in-valve procedures, and 3) Coronary bifurcation techniques (15%) optimizing stent deployment. These span Cardiovascular Revascularization Medicine , Journal of Invasive Cardiology , and Circulation journals. Scientific recognition includes: Fujisawa Travel Award (2003) Multiple Roland Burns Endowment Awards for clinical case excellence (2000-2001) Regional ACP Chapter Best Clinical Case Presentation (2001) As Principal Investigator on $700k+ in active industry grants (Abbott, Novo Nordisk, XyloCor), he leads trials on mitral valve systems and myocardial infarction outcomes. His VA Medical Center catheterization lab serves as the operational hub for these translational studies, with recent collaborations expanding into underrepresented population research through PCORI funding. The Cardiac Catheterization Laboratory at Cincinnati VA Medical Center functions as his primary research ecosystem, integrating clinical care with diagnostic innovation in structural heart disease and complex coronary interventions.

پروفایل رسمی دانشگاه

Megan Madonnaمشاهده پروفایل

استادیار

Duke UniversityUnited States

Megan Madonna is an Assistant Research Professor in the Department of Biomedical Engineering at Duke University, where she earned her Ph.D. in 2020. She teaches multiple Bass Connections research teams (ISS 796T/795T/396T/395T) focused on Information, Society & Culture, alongside engineering project courses including BME 493/494, BME 462L, BME 791, and EGR 393. Her research centers on optical metabolic imaging to investigate cancer metabolism, particularly in breast cancer subtypes. She develops advanced multi-probe and multi-scale imaging platforms capable of simultaneously quantifying metabolic and vascular endpoints such as fatty acid uptake, mitochondrial activity, and oxygen saturation in vivo. Her work specifically targets chemoresistance mechanisms in triple-negative and Her2+ breast cancer, identifying metabolic vulnerabilities during residual disease and recurrence. Analysis of her 15 most recent publications reveals a consistent focus on translating optical imaging techniques into clinical applications for cancer therapy guidance. Her work demonstrates strong interdisciplinary collaboration, particularly with Dr. Nimmi Ramanujam's lab, and spans from fundamental metabolic imaging development to clinical implications for chemotherapy monitoring. Dr. Madonna actively mentors students through graduate independent study (BME 791) and capstone projects (BME 493/494), while leading interdisciplinary Bass Connections teams that integrate engineering with societal considerations. She contributes to Duke's Global Women's Health Technologies ecosystem through her editorial work on gender-specific biomedical research.

پروفایل رسمی دانشگاه

Catherine Lesley Blakeمشاهده پروفایل

استاد

University of Illinois Urbana-ChampaignUnited States

Catherine Lesley Blake serves as Professor and Associate Dean for Academic Affairs in the School of Information Sciences (iSchool) at the University of Illinois at Urbana-Champaign. She additionally holds a joint appointment as a Health Innovation Professor in the Carle Illinois College of Medicine and maintains a courtesy appointment in Computer Science. Her extensive affiliations include the National Center for Supercomputing Applications (NCSA), the Illinois Informatics Institute (I3), and the Personalized Nutrition Initiative (PNI). Dr. Blake's research explores both human and automated methods to synthesize evidence from text, with nearly two decades of experience in text mining and natural language processing, primarily in biomedicine. Her work centers around the Claim Framework, which provides both a conceptual framework and automated methods that extract key findings from empirical studies in medicine, toxicology, and epidemiology. Her research spans diverse areas including chemical risk assessment, health data literacy, exposome analysis, and socio-technical data analytics. She has also explored text mining applications in humanities to detect authorship from movie reviews and in news stories for textual entailment recognition. Her publication portfolio demonstrates strong trends toward applying NLP and text mining techniques to health-related problems, particularly in chemical risk assessment, cancer research, and evidence-based medicine. The most recent works show increasing focus on using semantics to scale up evidence-based chemical risk assessments, analyzing exposome factors that impact cancer, and developing methods for automated systematic reviews. These publications reveal a consistent trajectory of applying computational methods to solve complex biomedical and environmental health problems. JASIST Best Paper Award for collaborative information synthesis papers Honorable mention at iConference (2013) for identifying claims in social science literature Principal Investigator for the NSF's Midwest Big Data Innovation Hub Recipient of multiple NSF, NIH, and IMLS grants totaling over $5 million As an educator and mentor, Dr. Blake has supervised numerous doctoral students including Jooho Lee, Henry Gabb, and Ana Lucic who have gone on to successful careers in academia and industry. She currently mentors Ryan Wang, George Vazquez, Don Keefer, and Jaemin Yang. Her grant portfolio includes significant funding from NSF, NIH, IMLS, VA, and industry partners like CISCO, with recent projects focusing on health data literacy ambassadors, chemical risk assessment, and AI for social impact. She regularly teaches courses including Database Design & Prototyping (IS455) and Text Mining (IS567). Dr. Blake leads multiple research initiatives including the Midwest Big Data Innovation Hub, which drives efforts to use AI for social impact in the region. Her work on the Claim Framework has established a robust infrastructure for evidence-based discovery, while her projects with the Personalized Nutrition Initiative and Illinois Informatics Institute demonstrate strong interdisciplinary collaboration across campus. Current research teams focus on developing methods to harness exposome factors that impact cancer, creating health data literacy programs for middle schoolers, and using text mining to identify privacy statement facets.

پروفایل رسمی دانشگاه